查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586431

特发性肺纤维化治疗市场，规模，占有率，趋势，产业分析报告:各类药物，各给药途径，各流通管道，各地区 - 市场预测，2025年～2034年

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的一项新研究，全球特发性肺纤维化治疗市场预计到 2034 年将达到 78.1 亿美元。该研究报告对当前市场动态提供了详细的见解，并对未来市场成长进行了分析。

特发性肺纤维化治疗市场受到生活方式改变的显着推动，例如吸烟和久坐行为的增加，以及接触污染物的增加。这些因素导致包括特发性肺纤维化 (IPF) 在内的肺部疾病盛行率不断上升，因为恶劣的空气品质和不健康的生活习惯会影响呼吸系统健康。此外，人们对特发性肺纤维化及其风险因素的认识不断提高，促进了早期诊断和治疗。随着生活方式的不断变化，未来几年对有效的特发性肺纤维化药物的需求预计将上升。

特发性肺纤维化盛行率的上升正在推动特发性肺纤维化治疗市场的成长。根据美国国立卫生研究院的数据，2021 年特发性肺纤维化的盛行率为每 10 万人口 36 例。人们认识的提高和诊断方法的改进使得早期发现疾病变得更加容易，从而扩大了寻求治疗的患者群体。因此，特发性肺纤维化盛行率的不断上升加上诊断方法的进步，大大增加了对有效治疗方案的需求，从而对市场成长产生了积极影响。

由于特发性肺纤维化是一种在老年人中特别普遍的疾病，预计在预测期内，全球老年人口的增加将显着推动特发性肺纤维化治疗市场的发展。在欧盟，超过 21.3% 的人口年龄在 65 岁或以上，对有效治疗的需求日益增长。这种人口趋势可能会导致特发性肺纤维化治疗的需求大幅增加。

特发性肺纤维化治疗市场报告重点

根据给药途径，预计口服剂型在预测期内将在全球市场上实现显着的复合年增长率。这种成长归功于多种优势，包括易于使用和门诊管理的可能性。

根据分销管道，医院药房部门在 2024 年占据了市场最大的收入占有率，这归因于住院率的提高以及需要高级治疗的患者可以获得专门的医疗服务。

由于其先进的医疗基础设施，北美将在 2024 年占据全球特发性肺纤维化治疗市场的最大收入占有率

由于製药製造业的投资增加，印度特发性肺纤维化治疗市场预计在预测期内将大幅成长。

全球主要的市场参与者包括F． Hoffmann-La Roche Ltd，Boehringer Ingelheim International GmbH，Bristol-Myers Squibb Company，Medicinova, Inc，Merck &Co, Inc，Galapagos NV，Novartis AG，Fibrogen, Inc.等。

目录

第1章 简介

第2章 摘要整理

第3章 调查手法

第4章 全球特发性肺纤维化治疗市场洞察

  • 市场概述
  • 特发性肺纤维化治疗市场动态
    • 促进因素和机会
      • 老龄人口增加推动市场成长
      • 诊断方法的进步正在扩大市场规模
    • 阻碍因素与课题
      • 有限的治疗选择
  • PESTEL分析
  • 特发性肺纤维化治疗市场趋势
  • 价值链分析
  • COVID-19影响分析

第5章 全球特发性肺纤维化治疗市场:各类药物

  • 主要调查结果
  • 简介
  • 吡非尼酮
  • Nintedanib
  • 干扰素γ1b
  • 其他

第6章 全球特发性肺纤维化治疗市场:各给药途径

  • 主要调查结果
  • 简介
  • 口服
  • 注射可能
  • 其他

第7章 全球特发性肺纤维化治疗市场:各流通管道

  • 主要调查结果
  • 简介
  • 医院药局
  • 零售药局
  • 其他

第8章 全球特发性肺纤维化治疗市场:各地区

  • 主要调查结果
  • 简介
    • 特发性肺纤维化治疗市场评估:地区，2020年～2034年
  • 北美
    • 北美:各类药物，2020年～2034年
    • 北美:各给药途径，2020年～2034年
    • 北美:各流通管道，2020年～2034年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:各类药物，2020年～2034年
    • 欧洲:各给药途径，2020年～2034年
    • 欧洲:各流通管道，2020年～2034年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 亚太地区:各类药物，2020年～2034年
    • 亚太地区:各给药途径，2020年～2034年
    • 亚太地区:各流通管道，2020年～2034年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 中东及非洲:各类药物，2020年～2034年
    • 中东·非洲:各给药途径，2020年～2034年
    • 中东·非洲:各流通管道，2020年～2034年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲
  • 南美
    • 南美:各类药物，2020年～2034年
    • 南美:各给药途径，2020年～2034年
    • 南美:各流通管道，2020年～2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第9章 竞争情形

  • 扩大和收购的分析
    • 扩大
    • 收购
  • 联盟/合作/协定/公开

第10章 企业简介

  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Medicinova, Inc
  • Merck & Co., Inc.
  • Galapagos NV
  • Novartis AG
  • Fibrogen, Inc.
  • Avalyn Pharma Inc.
  • Promedior, Inc.
Product Code: PM5148

The global idiopathic pulmonary fibrosis treatment market size is expected to reach USD 7.81 billion by 2034, according to a new study by Polaris Market Research. The report "Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The idiopathic pulmonary fibrosis treatment market is significantly driven by changing lifestyle habits, such as rising smoking consumption and sedentary behavior, as well as increasing exposure to pollutants. These factors contribute to the rising incidence of lung diseases, including IPF, as poor air quality and unhealthy habits impact respiratory health. Additionally, the growing awareness of idiopathic pulmonary fibrosis and its risk factors encourages earlier diagnosis and treatment. As lifestyles continue to evolve, the demand for effective idiopathic pulmonary fibrosis therapies is expected to rise in the coming years.

The rising prevalence of idiopathic pulmonary fibrosis is driving the growth of the idiopathic pulmonary fibrosis treatment market. According to the National Institutes of Health, the prevalence of idiopathic pulmonary fibrosis was 36 cases per 100,000 people in 2021. The growing awareness and improving diagnostic methods facilitate earlier disease identification, expanding the patient population seeking treatment. Consequently, the combination of increasing idiopathic pulmonary fibrosis prevalence and advancements in diagnostics is significantly boosting demand for effective treatment options, positively impacting the market growth.

The growing number of geriatrics worldwide is expected to significantly drive the idiopathic pulmonary fibrosis treatment market during the forecast period, as older adults are particularly susceptible to the disease. In the European Union, over 21.3% of the population is aged 65 and older, highlighting the increasing demand for effective treatments. This demographic trend will likely lead to a substantial rise in the need for idiopathic pulmonary fibrosis therapies.

Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights

Based on route of administration, the oral segment is anticipated to register a significant CAGR in the global market during the forecast period. This growth is attributed to its several advantages, including ease of use and potential of outpatient management.

By distribution channel, the hospital pharmacies segment accounted for the largest revenue share of the market in 2024 due to increasing hospitalization rates and the availability of specialized care for patients requiring advanced treatments.

In 2024, North America accounted for the largest revenue share of the global idiopathic pulmonary fibrosis treatment market due to its advanced medical infrastructure

The idiopathic pulmonary fibrosis treatment market in India is projected for significant growth during the forecast period due to the increased investments in its pharmaceutical manufacturing sector.

A few global key market players are F. Hoffmann-La Roche Ltd; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Medicinova, Inc; Merck & Co., Inc.; Galapagos NV; Novartis AG; and Fibrogen, Inc.

Polaris Market Research has segmented the idiopathic pulmonary fibrosis treatment market report on the basis of drug class, route of administration, distribution channel, and region:

By Drug Class Outlook (Revenue - USD Billion, 2020-2034)

  • Pirfenidone
  • Nintedanib
  • Interferon Gammato1b
  • Others
  • By Route of Administration (Revenue - USD Billion, 2020-2034)
  • Oral
  • Injectable
  • Others
  • By Distribution Channel (Revenue - USD Billion, 2020-2034)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Idiopathic Pulmonary Fibrosis Treatment Market Insights

  • 4.1. Idiopathic Pulmonary Fibrosis Treatment Market - Market Snapshot
  • 4.2. Idiopathic Pulmonary Fibrosis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Geriatric Population Are Driving Market Growth
      • 4.2.1.2. Advancement in Diagnostic Methods is Propelling Market Size
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Treatment Options
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Idiopathic Pulmonary Fibrosis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • 5.3. Pirfenidone
    • 5.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Pirfenidone, by Region, 2020-2034 (USD billion)
  • 5.4. Nintedanib
    • 5.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Nintedanib, by Region, 2020-2034 (USD billion)
  • 5.5. Interferon Gammato1b
    • 5.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Interferon Gammato1b, by Region, 2020-2034 (USD billion)
  • 5.6. Others
    • 5.6.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)

6. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • 6.3. Oral
    • 6.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Oral, by Region, 2020-2034 (USD billion)
  • 6.4. Injectable
    • 6.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Injectable, by Region, 2020-2034 (USD billion)
  • 6.5. Others
    • 6.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)

7. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD billion)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Retail Pharmacies, by Region, 2020-2034 (USD billion)
  • 7.5. Others
    • 7.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)

8. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Idiopathic Pulmonary Fibrosis Treatment Market Assessment, By Geography, 2020-2034 (USD billion)
  • 8.3. Idiopathic Pulmonary Fibrosis Treatment Market - North America
    • 8.3.1. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.3.2. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.3.3. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.3.4. Idiopathic Pulmonary Fibrosis Treatment Market - U.S.
      • 8.3.4.1. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.3.4.2. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.3.4.3. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.3.5. Idiopathic Pulmonary Fibrosis Treatment Market - Canada
      • 8.3.5.1. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.3.5.2. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.3.5.3. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.4. Idiopathic Pulmonary Fibrosis Treatment Market - Europe
    • 8.4.1. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.4.2. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.4.3. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.4. Idiopathic Pulmonary Fibrosis Treatment Market - UK
      • 8.4.4.1. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.4.2. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.4.3. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.5. Idiopathic Pulmonary Fibrosis Treatment Market - France
      • 8.4.5.1. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.5.2. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.5.3. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.6. Idiopathic Pulmonary Fibrosis Treatment Market - Germany
      • 8.4.6.1. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.6.2. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.6.3. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.7. Idiopathic Pulmonary Fibrosis Treatment Market - Italy
      • 8.4.7.1. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.7.2. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.7.3. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.8. Idiopathic Pulmonary Fibrosis Treatment Market - Spain
      • 8.4.8.1. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.8.2. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.8.3. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.9. Idiopathic Pulmonary Fibrosis Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.9.2. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.9.3. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.10. Idiopathic Pulmonary Fibrosis Treatment Market - Russia
      • 8.4.10.1. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.10.2. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.10.3. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.11. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.11.2. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.11.3. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.5. Idiopathic Pulmonary Fibrosis Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.5.2. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.5.3. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.4. Idiopathic Pulmonary Fibrosis Treatment Market - China
      • 8.5.4.1. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.4.2. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.4.3. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.5. Idiopathic Pulmonary Fibrosis Treatment Market - India
      • 8.5.5.1. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.5.2. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.5.3. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.6. Idiopathic Pulmonary Fibrosis Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.6.2. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.6.3. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.7. Idiopathic Pulmonary Fibrosis Treatment Market - Japan
      • 8.5.7.1. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.7.2. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.7.3. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.8. Idiopathic Pulmonary Fibrosis Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.8.2. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.8.3. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.9. Idiopathic Pulmonary Fibrosis Treatment Market - South Korea
      • 8.5.9.1. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.9.2. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.9.3. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.10. Idiopathic Pulmonary Fibrosis Treatment Market - Australia
      • 8.5.10.1. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.10.2. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.10.3. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.11. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.11.2. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.11.3. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.6. Idiopathic Pulmonary Fibrosis Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.6.2. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.6.3. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.4. Idiopathic Pulmonary Fibrosis Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.4.2. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.4.3. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.5. Idiopathic Pulmonary Fibrosis Treatment Market - UAE
      • 8.6.5.1. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.5.2. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.5.3. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.6. Idiopathic Pulmonary Fibrosis Treatment Market - Israel
      • 8.6.6.1. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.6.2. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.6.3. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.7. Idiopathic Pulmonary Fibrosis Treatment Market - South Africa
      • 8.6.7.1. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.7.2. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.7.3. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.8. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.8.2. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.8.3. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.7. Idiopathic Pulmonary Fibrosis Treatment Market - Latin America
    • 8.7.1. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.7.2. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.7.3. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.4. Idiopathic Pulmonary Fibrosis Treatment Market - Mexico
      • 8.7.4.1. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.4.2. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.4.3. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.5. Idiopathic Pulmonary Fibrosis Treatment Market - Brazil
      • 8.7.5.1. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.5.2. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.5.3. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.6. Idiopathic Pulmonary Fibrosis Treatment Market - Argentina
      • 8.7.6.1. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.6.2. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.6.3. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.7. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.7.2. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.7.3. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. F. Hoffmann-La Roche Ltd
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Boehringer Ingelheim International GmbH
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bristol-Myers Squibb Company
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Medicinova, Inc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Merck & Co., Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Galapagos NV
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novartis AG
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Fibrogen, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Avalyn Pharma Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Promedior, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables:

  • Table 1 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 2 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 3 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 4 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 5 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 6 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 7 U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 8 U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 9 U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 10 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 11 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 12 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 13 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 14 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 15 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 16 UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 17 UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 18 UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 19 France: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 20 France: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 21 France: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 22 Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 23 Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 24 Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 25 Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 26 Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 27 Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 28 Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 29 Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 30 Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 31 Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 32 Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 33 Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 34 Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 35 Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 36 Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 37 Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 38 Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 39 Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 40 Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 41 Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 42 Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 43 China: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 44 China: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 45 China: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 46 India: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 47 India: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 48 India: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 49 Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 50 Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 51 Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 52 Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 53 Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 54 Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 55 Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 56 Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 57 Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 58 South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 59 South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 60 South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 61 Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 62 Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 63 Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 64 Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 65 Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 66 Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 67 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 68 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 69 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 70 Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 71 Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 72 Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 73 UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 74 UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 75 UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 76 Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 77 Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 78 Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 79 South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 80 South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 81 South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 82 Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 83 Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 84 Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 85 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 86 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 87 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 88 Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 89 Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 90 Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 91 Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 92 Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 93 Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 94 Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 95 Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 96 Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 97 Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 98 Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 99 Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • List of Figures:
  • Figure 1. Global Idiopathic Pulmonary Fibrosis Treatment Market, 2020-2034 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2024 & 2034 (USD billion)
  • Figure 8. Market by Route of Administration
  • Figure 9. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2024 & 2034 (USD billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2024 & 2034 (USD billion)
  • Figure 12. Global Idiopathic Pulmonary Fibrosis Treatment Market Assessment, By Geography, 2020-2034 (USD billion)
  • Figure 13. Strategic Analysis - Global Idiopathic Pulmonary Fibrosis Treatment Market